547 related articles for article (PubMed ID: 9287957)
21. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
[TBL] [Abstract][Full Text] [Related]
22. Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease.
Gicheru MM; Olobo JO; Anjili CO
Exp Parasitol; 1997 Feb; 85(2):109-16. PubMed ID: 9030661
[TBL] [Abstract][Full Text] [Related]
23. Phlebotomus papatasi sand fly salivary gland lysate down-regulates a Th1, but up-regulates a Th2, response in mice infected with Leishmania major.
Mbow ML; Bleyenberg JA; Hall LR; Titus RG
J Immunol; 1998 Nov; 161(10):5571-7. PubMed ID: 9820534
[TBL] [Abstract][Full Text] [Related]
24. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response.
Alexander J; Coombs GH; Mottram JC
J Immunol; 1998 Dec; 161(12):6794-801. PubMed ID: 9862710
[TBL] [Abstract][Full Text] [Related]
25. Functional plasticity of the LACK-reactive Vbeta4-Valpha8 CD4(+) T cells normally producing the early IL-4 instructing Th2 cell development and susceptibility to Leishmania major in BALB / c mice.
Maillard I; Launois P; Himmelrich H; Acha-Orbea H; Diggelmann H; Locksley RM; Louis JA
Eur J Immunol; 2001 Apr; 31(4):1288-96. PubMed ID: 11298356
[TBL] [Abstract][Full Text] [Related]
26. Control of Leishmania major infection in BALB/c mice by inhibition of early lymphocyte entry into peripheral lymph nodes.
Laskay T; Wittmann I; Diefenbach A; Röllinghoff M; Solbach W
J Immunol; 1997 Feb; 158(3):1246-53. PubMed ID: 9013966
[TBL] [Abstract][Full Text] [Related]
27. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.
Piedrafita D; Xu D; Hunter D; Harrison RA; Liew FY
J Immunol; 1999 Aug; 163(3):1467-72. PubMed ID: 10415048
[TBL] [Abstract][Full Text] [Related]
28. Leishmania major induces distinct neutrophil phenotypes in mice that are resistant or susceptible to infection.
Charmoy M; Megnekou R; Allenbach C; Zweifel C; Perez C; Monnat K; Breton M; Ronet C; Launois P; Tacchini-Cottier F
J Leukoc Biol; 2007 Aug; 82(2):288-99. PubMed ID: 17449725
[TBL] [Abstract][Full Text] [Related]
29. Leishmania major: differential resistance to infection in C57BL/6 (high interferon-alpha/beta) and congenic B6.C-H-28c (low interferon-alpha/beta) mice.
Shankar AH; Morin P; Titus RG
Exp Parasitol; 1996 Nov; 84(2):136-43. PubMed ID: 8932763
[TBL] [Abstract][Full Text] [Related]
30. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis.
Stamm LM; Räisänen-Sokolowski A; Okano M; Russell ME; David JR; Satoskar AR
J Immunol; 1998 Dec; 161(11):6180-8. PubMed ID: 9834104
[TBL] [Abstract][Full Text] [Related]
31. BCL-6-deficient mice reveal an IL-4-independent, STAT6-dependent pathway that controls susceptibility to infection by Leishmania major.
Dent AL; Doherty TM; Paul WE; Sher A; Staudt LM
J Immunol; 1999 Aug; 163(4):2098-103. PubMed ID: 10438949
[TBL] [Abstract][Full Text] [Related]
32. Dissociation of disease susceptibility, inflammation and cytokine profile in lmr1/2 congenic mice infected with Leishmania major.
Elso C; Kumar B; Smyth G; Foote S; Handman E
Genes Immun; 2004 May; 5(3):188-96. PubMed ID: 14762398
[TBL] [Abstract][Full Text] [Related]
33. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.
Sadick MD; Heinzel FP; Shigekane VM; Fisher WL; Locksley RM
J Immunol; 1987 Aug; 139(4):1303-9. PubMed ID: 3112230
[TBL] [Abstract][Full Text] [Related]
34. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
Rafati S; Ghaemimanesh F; Zahedifard F
Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
[TBL] [Abstract][Full Text] [Related]
35. Mice lacking NK cells develop an efficient Th1 response and control cutaneous Leishmania major infection.
Satoskar AR; Stamm LM; Zhang X; Satoskar AA; Okano M; Terhorst C; David JR; Wang B
J Immunol; 1999 Jun; 162(11):6747-54. PubMed ID: 10352294
[TBL] [Abstract][Full Text] [Related]
36. Co-infected C57BL/6 mice mount appropriately polarized and compartmentalized cytokine responses to Litomosoides sigmodontis and Leishmania major but disease progression is altered.
Lamb TJ; Graham AL; Le Goff L; Allen JE
Parasite Immunol; 2005 Sep; 27(9):317-24. PubMed ID: 16149989
[TBL] [Abstract][Full Text] [Related]
37. Leishmania major: targeting IL-4 in successful immunomodulation of murine infection.
Wakil AE; Wang ZE; Locksley RM
Exp Parasitol; 1996 Nov; 84(2):214-22. PubMed ID: 8932771
[TBL] [Abstract][Full Text] [Related]
38. Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain.
Alleva DG; Kaser SB; Beller DI
J Immunol; 1998 Dec; 161(12):6878-84. PubMed ID: 9862720
[TBL] [Abstract][Full Text] [Related]
39. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
40. Leishmania major-infected C3H mice treated with anti-IL-12 mAb develop but do not maintain a Th2 response.
Hondowicz BD; Scharton-Kersten TM; Jones DE; Scott P
J Immunol; 1997 Nov; 159(10):5024-31. PubMed ID: 9366430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
